Articles in 2011

Erratum: Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

• C A DeRosa
• B Furusato
• G Petrovics

Body mass index and risk of BPH: a meta-analysis

• S Wang
• Q Mao
• L Xie

Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH

• A Aweimer
• T Stachon
• A Stachon

Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior

• G Gueron
• A De Siervi
• E Vazquez

Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists

• M A Gorin
• A Eldefrawy
• M S Soloway

Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme

• M Nomura
• K Ito
• K Suzuki

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

• C A DeRosa
• B Furusato
• G Petrovics

PSA screening: determinants of primary-care physician practice patterns

• G E Tasian
• M R Cooperberg
• J M Chan

Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study

• K Shafique
• M J Proctor
• D S Morrison

Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies

• C B Anderson
• A L Pyle
• D A Barocas

Cause-specific mortality following radical prostatectomy

• S Shikanov
• M Kocherginsky
• S E Eggener

Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer

• M J Alvarez-Cubero
• C Entrala
• J M Cozar

Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells

• S M Manohar
• A A Padgaonkar
• K S Joshi

Erratum: Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines

• M St John Floyd Jr
• S J Teahan
• R W G Watson

Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer

• A K Wu
• A C Reese
• K Shinohara

Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer

• A Spitz
• J M Young
• K Chwalisz

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

• J E Ward
• T Karrison
• E M Posadas

Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence

• J Teishima
• K Shoji
• A Matsubara

Neighborhood deprivation and prostate cancer mortality: a multilevel analysis from Sweden

• X Li
• K Sundquist
• J Sundquist

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy

• S Miyamoto
• K Ito
• H Yamanaka